Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Case Review: MRI Leads to Non-Rheumatic Diagnosis Surprise

Anna Helena Jonsson, MD, PhD, & Julia F. Charles, MD, PhD  |  May 17, 2018

Rheumatologists often rely on magnetic resonance imaging (MRI) in the evaluation of suspected muscular diseases. Here, we describe a case in which unexpected findings on MRI pointed to a diagnosis rarely considered as a mimicker of rheumatologic disease. The Case A 19-year-old man of Middle Eastern descent was admitted to our hospital for evaluation of…

Filed under:Conditions Tagged with:anorexia nervosamagnetic resonance imagingMRI

IgG4-Related Kidney Disease: Diagnostics, Manifestations, & More

IgG4-Related Kidney Disease: Diagnostics, Manifestations & More

Despina Michailidou, MD, PhD, & Paul Cohen, MD   |  May 17, 2018

Immunoglobin G4-related disease (IgG4-RD) is a rare fibro-inflammatory disease of unknown etiology that has been recently recognized. It can cause fibro-inflammatory masses in almost every organ of the body and is associated with dense lymphoplasmacytic infiltration of IgG4-postitive plasma cells, storiform fibrosis and elevated levels of serum IgG4.1 IgG4-RD is a systemic disease that may…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:fibroinflammatoryIgG4 related diseaseIgG4-RDkidney disease

Genetics Suggest Adult & Child Arthritis Aren’t So Different

Kurt Ullman  |  April 26, 2018

There has long been a wall separating adult rheumatologists from pediatric rheumatologists. A recent review article published in the January edition of Arthritis & Rheumatology (A&R) suggests that genetics, rather than age, may be a better way to categorize forms of primary inflammatory arthritis across the lifespan.1 “Pediatric and adult rheumatologists don’t generally interact that…

Filed under:Conditions Tagged with:adult arthritisArthritisJuvenile arthritispediatric arthritis

Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis

Reuters Staff  |  April 26, 2018

NEW YORK (Reuters Health)—The RANKL inhibitor denosumab is superior to the bisphosphonate risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomized controlled study. “Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and increases the risk of…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesbone mineral density (BMD)denosumabGlucocorticoidsOsteoporosisosteoporosis treatmentsrisedronate

AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023

Tamara Mathias  |  April 8, 2018

(Reuters)—AbbVie Inc. on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc. that would fend off U.S. competition of their biosimilar version to blockbuster drug, adalimumab (Humira), until 2023. This is the second deal AbbVie has signed over the past year as it tries to safeguard patents on Humira,…

Filed under:Biologics/DMARDsDrug Updates Tagged with:AbbVieadalimumabBiosimilarsHumiraSamsung Bioepis

Many in U.S. Take More Calcium Supplements than Necessary

Lisa Rapaport  |  March 30, 2018

(Reuters Health)—Some adults in the U.S. who use supplements to get their daily requirement of calcium are taking higher doses than necessary, a recent study suggests. Researchers examined nationally representative survey data on dietary habits and vitamin and supplement use collected between 1999 and 2014 from 42,038 adults. About one in 20 adults got a…

Filed under:Drug Updates Tagged with:calcium supplementsPamela Lutsey

Joan M. Von Feldt, MD, MSEd: A Shopper with a Cause

Carol Patton  |  March 19, 2018

Joan M. Von Feldt, MD, MSEd, loves fashion—everything from the feel of natural fabrics and the fit of a well-crafted garment to mixing and matching colors and textures. As a professor of medicine at the University of Pennsylvania and editor in chief of the Journal of Clinical Rheumatology, she enjoys being well dressed and, like…

Filed under:AudioProfilesRheum After 5 Tagged with:Joan M. Von FeldtProfiles

Updates on Giant Cell Arteritis

Susan Bernstein  |  March 19, 2018

SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

Filed under:Meeting ReportsVasculitis Tagged with:ACR/ARHP Annual Meetinggiant cell arteritis (GCA)

PhuShutter / shutterstock.com

The FDA Approved Several New Rheumatology Drugs in 2017

Larry Beresford  |  March 18, 2018

SAN DIEGO—In a session at the 2017 ACR/ARHP Annual Meeting, Kam Nola, PharmD, MS, professor in the College of Pharmacy and vice chair in the Department of Pharmacy Practice at Lipscomb University in Nashville, Tenn., updated participants on new medications and new indications for rheumatology treatments and safety labeling changes approved by the U.S. Food…

Filed under:Drug UpdatesMeeting Reports Tagged with:abaloparatideACR/ARHP Annual MeetingAllopurinolbelimumabbrodalumabguselkumablesinuradMethotrexatesarilumabtocilizumab

SLE Remission: The Treat-to-Target Approach

Susan Bernstein  |  March 17, 2018

SAN DIEGO—Treatment strategies for systemic lupus erythematosus (SLE) have changed a great deal over the years, but progress has been slow and inadequate. According to a 2011 survey, many patients with lupus still report that they have a low quality of life due to their health problems.1 Rheumatologists face the challenge to develop more successful…

Filed under:Meeting ReportsSystemic Lupus Erythematosus Tagged with:ACR/ARHP Annual MeetingLupusRemissionSLE

  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 83
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences